

ASX Market Announcements
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

RE: ADHERIUM LIMITED - RELEASE OF SECURITIES FROM ESCROW

In connection with the quotation of Adherium Limited's fully paid ordinary shares (Shares) on the Australian Securities Exchange (**ASX**) on 26 August 2015 certain security holders in the Company were required to enter into ASX restriction agreements. These agreements restricted the relevant security holders from dealing in their securities for periods of up to 24 months from the date of quotation.

In accordance with ASX Listing Rule 3.10A, Adherium advises that 35,494,024 fully paid ordinary shares of the Company will be released from mandatory ASX restriction on 26 August 2017.

Application for quotation of these fully paid ordinary shares will also be made following their release from restriction.

Yours faithfully



Rob Turnbull
CFO & Joint Company Secretary

ASX: ADR

ABN

24 605 352 510

Company Overview

Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.

Directors

Mr Thomas Lynch (Chair)
Mr Garth Sutherland (Founder)
Mr Jeremy Curnock Cook
Dr William Hunter
Mr Bruce McHarrie
Prof John Mills
Mr Bryan Mogridge

Chief Executive

Arik Anderson

Joint Company Secretaries

Mr Rob Turnbull
Mr Mark Licciardo

Registered Office

Collins Square, Tower 4
Level 18, 727 Collins Street
Melbourne, VIC 3000, Australia
+61 3 8657 5540

NZ Office

Level 2, 204 Quay Street
Auckland 1010
New Zealand

Investor Relations

investors@adherium.com

Websites

www.adherium.com
www.smartinhaler.com